Pow­er­ful Re­pub­li­can Chuck Grass­ley at­tacks No­var­tis CEO Narasimhan for ‘rep­re­hen­si­ble’ de­ci­sion to hide da­ta

Last month
People

Lit­tle De­ci­phera will hus­tle pos­i­tive PhI­II sur­vival da­ta on lead can­cer drug to the FDA in search of its first OK — shares soar

Last month
R&D

Make that 2 new US Big Phar­ma chiefs to­day, as No­var­tis re­makes top team

Last month
People
Pharma

Shift­ing fo­cus to on­col­o­gy, GSK re­cruits a can­cer vet as new chief of US phar­ma­ceu­ti­cals — adding an­oth­er woman to the top ranks of bio­phar­ma

Last month
People

Hu­mana takes aim at Mallinck­rodt's 'ill-got­ten' Ac­thar gains in law­suit

Last month
Pharma
Regulatory

A top an­a­lyst spot­lights a wave of biotech star­tups look­ing to cat­a­pult on­to Nas­daq — or get bought out

Last month
IPOs
Venture

Am­gen at­tor­neys win a megablock­buster patent case, deal­ing No­var­tis a se­vere set­back on biosim­i­lars play

Last month
Pharma

US sen­a­tors ac­cuse No­var­tis ex­ecs of greed for hid­ing ma­nip­u­lat­ed Zol­gens­ma da­ta — and the next step could af­fect the in­dus­try

Last month
Pharma
Regulatory

Melin­ta chief John John­son jumps ship — with the chair­man — from an­oth­er trou­bled an­tibi­otics play

Last month
People

Mys­tery solved? Nek­tar chief says 'soft­en­ing' in pa­tient re­spons­es to be­m­peg was a CMC is­sue — spurring a rout

Last month
R&D

Sarep­ta shares slammed on re­port gene ther­a­py Duchenne MD pa­tient was hos­pi­tal­ized, but the com­pa­ny says it is 'er­ro­neous'

Last month
Pharma
R&D

The FDA’s very pub­lic slap of No­var­tis’ red face is a warn­ing to the en­tire in­dus­try — don’t down­play it

Last month
Bioregnum

Bay­er is go­ing all in on next-gen stem cell biotech Blue­Rock, buy­ing out Ver­sant and founders for $600M

Last month
Cell/Gene Tx
Deals

Gilead­'s new­ly de­part­ed R&D chief re-emerges as CEO of a ri­val hep B biotech look­ing to make a come­back

Last month
People

Loxo chief Josh Bilenker steps in (tem­porar­i­ly) to head on­col­o­gy R&D at Eli Lil­ly as Levi Gar­raway steps out

Last month
People
Pharma

Rhythm Phar­ma­ceu­ti­cal­s' lead drug scores in piv­otal rare obe­si­ty tri­als

Last month
R&D

Faced with an­oth­er ethics scan­dal, No­var­tis CEO Vas Narasimhan as­sures an­a­lysts they tried to do 'the right thing'

Last month
Pharma
Regulatory

Gilead faces a hur­dle in its race for big, add-on OK for De­scovy as gener­ic Tru­va­da ri­vals loom

Last month
Pharma
R&D

Sanofi, Re­gen­eron post back-to-back wins with new OK and a fresh round of pos­i­tive PhI­II da­ta for their block­buster growth fran­chise

Last month
R&D

Close to a decade af­ter Eli Lil­ly killed it, Jef­frey Blue­stone's 'break­through' drug is back and be­ing steered to the FDA

Last month
R&D
Regulatory

Join­ing Chang and Bellde­grun, Rafael Ama­do takes a lead­ing R&D post in the next big cell ther­a­py rev­o­lu­tion

Last month
Cell/Gene Tx
People

David Apelian to steer TCR play at Pitt spin­out; Third Rock scoops Il­lu­mi­na ex­ec as CEO of can­cer de­tec­tion up­start

Last month
Peer Review

Bio­Marin ex­ecs make their case for he­mo­phil­ia gene ther­a­py as fret­ful an­a­lysts start to hedge their bets

Last month
R&D

At new­ly rechris­tened Rakuten Med­ical, Japan­ese bil­lion­aire Mik­i­tani ups the ante with an­oth­er megaround

Last month
Venture
First page Previous page 1234567 Next page Last page